Acute Respiratory Distress Syndrome (ARDS) Clinical Trials

Find Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Near You

Avalanche Phenomenon During Airways Opening in Acute Respiratory Distress Syndrome

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Acute respiratory distress syndrome accounts for 23% of mechanically ventilated patients and is associated with high mortality rate. Although life-saving, mechanical ventilation may worsen lung injury through two main mechanisms: lung overdistension and atelectrauma. Indeed, the cyclic opening and closure of airways during tidal ventilation may cause lung and bronchial injuries as suggested by animal models and autopsy findings. Complete airways closure has recently been described in 40% of patients with acute respiratory distress syndrome, and setting positive end-expiratory pressure above the airway opening pressure may limit atelectrauma. However, animal and mathematical models suggest that above the airway opening pressure, more distal airways open unevenly according to their own opening pressure, resulting in an avalanche-like phenomenon during lung inflation. This phenomenon has never been described in humans. A better understanding of the opening of airways in acute respiratory distress syndrome may help to limit ventilation-induced lung injury and to improve outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18

• Moderate-to-severe acute respiratory distress syndrome within the first 72 hours after meeting the Berlin definition criteria:

• Within 1 week of a known clinical insult or new or worsening respiratory symptoms;

• Bilateral opacities (not fully explained by effusions, lobar/lung collapse, or nodules);

• Respiratory failure not fully explained by cardiac failure or fluid overload;

• PaO2/FiO2 ≤ 200 mmHg with positive end-expiratory pressure ≥ 5 cmH2O.

• Absence of spontaneous breathing efforts

• Consent to participate to the study from the patient and/or its surrogate

Locations
Other Locations
France
CHU Poitiers
RECRUITING
Poitiers
Contact Information
Primary
Rémi Coudroy, MD, PhD
remi.coudroy@chu-poitiers.fr
+ 33 5 49 44 40 07
Backup
Céline DELETAGE
celine.deletage@chu-poitiers.fr
+33 5 49 44 38 54
Time Frame
Start Date: 2022-03-01
Estimated Completion Date: 2026-10
Participants
Target number of participants: 50
Sponsors
Leads: Poitiers University Hospital

This content was sourced from clinicaltrials.gov